Bristol arms itself for kidney-cancer fight as Keytruda threatens Opdivo’s share
Bristol-Myers Squibb investors have been dreading the arrival of Merck’s Keytruda in kidney cancer, one of Opdivo’s key growth areas. Bristol’s execs? Not so much. The company has been preparing for the launch of I-O-plus-TKI regimens—such as the marriage of Keytruda and Pfizer’s Inlyta that won FDA approval Monday, or the Bavencio-Inlyta duo that Pfizer… Read More »